ResearcherSouth China Normal UniversityActive in the last 2 years
Xiaodong Ma
Matched on ORCID iD 0000-0002-8351-2663; OpenAlex author ID A5009755528. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 7
2022: 1 paper · 2023: 1 paper · 2024: 2 papers
Papers 4
- Letrozole-Based Near-Infrared Dynamic Imaging Targeting Ductal-Vascular RhoJ From Pancreatic Intraepithelial Neoplasia to Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/adhm.202402913↗
- Characterization of tumor-associated endothelial cells and the development of a prognostic model in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbagen.2023.130545↗
- An autocatalytic multicomponent DNAzyme nanomachine for tumor-specific photothermal therapy sensitization in pancreatic cancer. First author DOI 10.1038/s41467-023-42740-2↗
- SQLE inhibition suppresses the development of pancreatic ductal adenocarcinoma and enhances its sensitivity to chemotherapeutic agents in vitro. Last author DOI 10.1007/s11033-022-07504-z↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zhi Cao · 2 shared papers, 2024 · strength 0.44
- Paper Characterization of tumor-associated endothelial cells and the development of a prognostic model in pancreatic ductal a… DOI 10.1016/j.bbagen.2023.130545↗
- Paper Letrozole-Based Near-Infrared Dynamic Imaging Targeting Ductal-Vascular RhoJ From Pancreatic Intraepithelial Neoplasia … DOI 10.1002/adhm.202402913↗
- Fengyun Zhao · 2 shared papers, 2022–2024 · strength 0.35
- Paper Letrozole-Based Near-Infrared Dynamic Imaging Targeting Ductal-Vascular RhoJ From Pancreatic Intraepithelial Neoplasia … DOI 10.1002/adhm.202402913↗
- Paper SQLE inhibition suppresses the development of pancreatic ductal adenocarcinoma and enhances its sensitivity to chemothe… DOI 10.1007/s11033-022-07504-z↗
- Jun Wu · 1 shared paper, 2024 · strength 0.26
- Xun Li · 1 shared paper, 2024 · strength 0.26
- Hongbo Zhang · 1 shared paper, 2023 · strength 0.18
- Jiaqi Yan · 1 shared paper, 2023 · strength 0.18
- Xian Shen · 1 shared paper, 2023 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.